Chris LaVictoire Mahai bought $10k of HQL
director at abrdn Life Sciences Investors. 527 shares at an average of $19.92, traded Jul 16, 2026, filed Jul 20, 2026.
Score components
- +15RoleDirector
- 0Trade size$10k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- 0Price contextNear the top of the 52-week range
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-26-085027, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 16, 2026 | POpen-market purchase Common Stock | +527 | $19.92 | $10k | 527 | Jul 20, 2026 |
Related signals
Other insiders at abrdn Life Sciences Investors and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 34Weak | HQLbuy abrdn Life Sciences Investors | Christian Pittard director | $134k 7,923 shares | - | |
| 33Weak | HQLsell abrdn Life Sciences Investors | Saba Capital Management, L.P. owner | $687k 48,612 shares | -2% | |
| 36Weak | HQLsell abrdn Life Sciences Investors | Saba Capital Management, L.P. owner | $906k 64,536 shares | -2% | |
| 18Weak | HQLsell abrdn Life Sciences Investors | Saba Capital Management, L.P. owner | $38k 2,726 shares | -0% | |
| 24Weak | HQLsell abrdn Life Sciences Investors | Saba Capital Management, L.P. owner | $216k 15,116 shares | -1% | |
| 24Weak | HQLsell abrdn Life Sciences Investors | Saba Capital Management, L.P. owner | $198k 14,083 shares | -0% | |
| 27Weak | HQLsell abrdn Life Sciences Investors | Saba Capital Management, L.P. owner | $330k 23,723 shares | -1% | |
| 12Weak | HQLsell abrdn Life Sciences Investors | Saba Capital Management, L.P. owner | $5,532 400 shares | -0% | |
| 23Weak | HQLsell abrdn Life Sciences Investors | Saba Capital Management, L.P. owner | $151k 10,710 shares | -0% | |
| 23Weak | HQLsell abrdn Life Sciences Investors | Saba Capital Management, L.P. owner | $145k 11,419 shares | -0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.